Literature DB >> 16842404

The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.

David M Burger, H Reinier Schwietert, E P H Colbers, Mark Becker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16842404      PMCID： PMC1885087          DOI： 10.1111/j.1365-2125.2006.02635.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.

Authors:  Y Khaliq; K Gallicano; I Seguin; K Fyke; G Carignan; D Bulman; A Badley; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

Authors:  J A H Droste; C P W G M Verweij-Van Wissen; D M Burger
Journal:  Ther Drug Monit       Date:  2003-06       Impact factor: 3.681

Review 3.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

Authors:  Takahisa Furuta; Naohito Shirai; Mitsushige Sugimoto; Akiko Nakamura; Akira Hishida; Takashi Ishizaki
Journal:  Drug Metab Pharmacokinet       Date:  2005-06       Impact factor: 3.614

Review 4.  Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

Authors:  Shogo Ozawa; Akiko Soyama; Mayumi Saeki; Hiromi Fukushima-Uesaka; Masaya Itoda; Satoru Koyano; Kimie Sai; Yasuo Ohno; Yoshiro Saito; Jun-Ichi Sawada
Journal:  Drug Metab Pharmacokinet       Date:  2004-04       Impact factor: 3.614

5.  Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.

Authors:  Vandana N Hirani; Judy L Raucy; Jerome M Lasker
Journal:  Drug Metab Dispos       Date:  2004-09-24       Impact factor: 3.922

6.  Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Authors:  Isabelle Pellegrin; Dominique Breilh; François Montestruc; Anne Caumont; Isabelle Garrigue; Philippe Morlat; Cécile Le Camus; Marie-Claude Saux; Hervé J A Fleury; Jean-Luc Pellegrin
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

7.  Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.

Authors:  David M Burger; Patricia W H Hugen; Rob E Aarnoutse; Richard M W Hoetelmans; Marielle Jambroes; Pythia T Nieuwkerk; Gerrit Schreij; Margriet M E Schneider; Marchina E van der Ende; Joep M A Lange
Journal:  Ther Drug Monit       Date:  2003-02       Impact factor: 3.681
  7 in total
  4 in total

1.  Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.

Authors:  Bharat D Damle; Howard Uderman; Pinaki Biswas; Penelope Crownover; Chang Lin; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

2.  Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Authors:  Sheng-Chang Wang; Ing-Kang Ho; Hsiao-Hui Tsou; Sheng-Wen Liu; Chin-Fu Hsiao; Chia-Hui Chen; Happy Kuy-Lok Tan; Linen Lin; Chi-Shin Wu; Lien-Wen Su; Chieh-Liang Huang; Yi-Hong Yang; Ming-Lun Liu; Keh-Ming Lin; Shu Chih Liu; Hsiao-Yu Wu; Hsiang-Wei Kuo; Andrew C H Chen; Yao-Sheng Chang; Yu-Li Liu
Journal:  OMICS       Date:  2013-09-09

3.  Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

Authors:  Déborah Hirt; France Mentré; Agnès Tran; Elisabeth Rey; Solange Auleley; Dominique Salmon; Xavier Duval; Jean-Marc Tréluyer
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

4.  CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.

Authors:  Akihiko Saitoh; Edmund Capparelli; Francesca Aweeka; Elizabeth Sarles; Kumud K Singh; Andrea Kovacs; Sandra K Burchett; Andrew Wiznia; Sharon Nachman; Terence Fenton; Stephen A Spector
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.